In light of rising competitive pressure, Allergan increased its investments in consumer and digital marketing programs, including new consumer campaigns for both Botox and Juvéderm. In Eye Care, while Ozurdex sales rose 18.8% to $30.3 million, Restasis sales fell 9.4% to $231.7 million. Restasis sales decreased due to lower selling price. Botox Therapeutic revenues were $397.6 million, up 5.8% year over year. On the call the company said that its share of new chronic migraine patients is 47%, stable from last quarter. It said that 2% of CGRP patients were switched from Botox.